Hanna consolidate • Cultures clash – commodity wins • Dependent on income derived from commodity joint ventures The First 6 Years • Globally organized along three strategic platforms • Non-core equity investment dispositions • Talent upgrades, discipline instilled throughout organization • New CEO hired to transform POL into specialty business �18 of 20 officers new • Implemented four pillar strategy • Nearly 50% of The Second 6 Years History of PolyOne – A Transformation • Focused on increasing volume, not profits • Heavily tied to cyclical markets 2000 2006 2012 The FormationThe Formation The TransformationThe Transformation The New PolyOneThe New PolyOne organization • Demonstrated ability to deliver • Nearly 50% of business operating income derived from Specialty Platform* • Specialty assets acquired *Pro forma for ColorMatrix acquisition Page 8 30% 50% 70% 90% $10 $12 $14 $16 $18 PolyOnePolyOne Stock Price S&P 500 (relative performance) Strategy and Execution Drive Results | | | | -50% -30% -10% 10% 30% $0 $2 $4 $6 $8 $10 2006 2007 2008 2009 2010 2011 2012 Page 9 Four Pillar Strategy The World’s Premier Provider of Specialized Polymer Materials, Services & Solutions Page 10 60% 80% 100% % o f O p e ra ti n g I n co m e * Old PolyOne Transformation 2012 Target “What We Said” Mix Shift Highlights Specialty Transformation Ahead of Schedule *Operating Income excludes Corporate Charges ** Pro Forma for the acquisition of ColorMatrix and divestiture of SunBelt 2% 34% 42% 50% >50% 0% 20% 40% 2005 2008 2011 2011** 2012 % o f O p e ra ti n g I n co m e * JV's PP&S Distribution Specialty Specialty OI $5M $46M $89M $117M “What We Said” Page 11 2007 2012 Target 2011 “Where we were” “What we said” “Where we are” 1) Operating Income % Specialty 3.2% 10% - 12% 8.9% PP&S 6.1% 8% - 10% 7.2% Pro forma ColorMatrix Proof of Performance Distribution 3.0% 4% - 5% 5.6% 2) Specialty Platform sss% of Operating Income 20% >50% 50% 3) Specialty Vitality Index 21% 35% - 40% 49% 4) ROIC* (pre-tax) 11% >15% 16% 5) Sales outside the US 37% >40% 40% *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 12 2011 Pro forma ColorMatrix 2015 Target “Where we are” “Where we expect to be” 1) Operating Income % Specialty 8.9% PP&S 7.2% 12 – 16% 9 – 12% Elevating our Expectations and Yours PP&S 7.2% Distribution 5.6% 2) Specialty Platform % of Operating Income 50% 3) ROIC* (after-tax) 10% 4) Adjusted Annual EPS Growth 3 yr CAGR = 71% 9 – 12% 6 – 7.5% 65 – 75% 15% Double Digit Expansion *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 13 • Four pillar strategy, coupled with our ability to execute is driving results • Strong leadership team driving growth & executing • Innovation and services provide differentiation and How do we get there? EPS: $2.50 Assumptions • High single digit organic revenue CAGR • Operating margins in mid range of 2015 targets • Housing starts at 85% of 50 year norm by 2015 • No investment in incremental PP&S capacity • Completion of 2-3 midsize accretive acquisitions • No divestitures • Remain comfortably below 3X Net Debt / EBITDA • No global recession 2011 Rev: $2.9B Adj.

ELECTRICAL PARTS MANUFACTURER H E A V Y D U T Y C O N N E C T O R S A N D A C C E S S O R I E S • Reduce material rematching and rejection through more efficient pre-testing • Improve processing efficiencies and color consistency in highly FR-filled and high-temperature resins • Achieve regulatory compliance across multiple resin families • Gain better supply chain control to manage scarcity of key engineering resins and changing resin producers • Offered eight UL 94-recognized sites in U.S. and Canada that perform comprehensive analytical, physical and mechanical testing • Provided increased speed to market and expedited design timelines for new products using existing standardized and pre- approved color palettes • Ensured regulatory compliance and security of supply OnColor™ UL 94 Colorants KEY REQUIREMENTS WHY AVIENT AVIENT SOLUTION QUALITY + SPEED TO MARKET LEARN MORE © 2023, Avient Corporation, All Rights Reserved https://www.avient.com/products/polymer-colorants/solid-color-masterbatches/oncolor-ul94-colorants

Glucose Monitoring App Snapshot draft MEDICAL DEVICE OEM C O N T I N U O U S G L U C O S E M O N I T O R I N G S Y S T E M • Adapt to strict processing requirements of a secondary operation put in place to manufacture a new device model • Meet material size and thickness requirements while achieving desired color target • Overcome material unpredictability and sensitivity to heat, light and moisture • Minimize impact of supply chain instability and changes • Offered support for processing under low pressure conditions and at every stage of manufacturing • Performed extensive R&D work to consistently deliver the customer’s color target of a hard-to-achieve light gray • Effectively addressed all material challenges and sensitivities • Provided regular ‘summaries of understanding’ to keep up with changing forecasts and ordering patterns Mevopur™ Pre-color Formulation KEY REQUIREMENTS WHY AVIENT?

MEDICAL EQUIPMENT MANUFACTURER S U R G I C A L X - R A Y G L A S S E S • Replace lead while providing uniform shielding performance • Radiation shielding up to 140KeV • Improve glasses design • Compliance with Radiation Protection Regulation: Adult eye exposure must be below 20 mSv per calendar year • Conducted extensive testing to ensure comparable and uniform shielding performance • Improved geometric flexibility • Lowered shielding component costs 30-50% by eliminating machining and assembly steps (associated with lead) • Reduced weight of the glasses and enabled a more ergonomic design • Eliminated disposal concerns associated with lead Trilliant™ XR Lead Replacement Thermoplastics KEY REQUIREMENTS WHY AVIENT?

Wire & cable manufacturer WIRE & CABLE MANUFACTURER A E R O N A U T I C D A T A T R A N S M I S S I O N C A B L E S • Permanent contrast marking meeting aerospace industry standards SAE AS4373F and EN-3475-706 • Benign marking that, compared to infrared (IR) laser marking, will not damage the jacket surface • Elevated temperature performance in corrosive environments, maintaining dielectric properties under continuous service • No vital optical fiber or data transmission cable interference • Demonstrated fluorinated ethylene propylene (FEP) application expertise incorporating laser marks • Provided formulation expertise in PTFE alternatives • Delivered a high-quality product with no clumping during the extrusion process • Offered a proven array of specific aeronautic colors • Provided commercial, technical, and operational support KEY REQUIREMENTS APPEARANCE + PERFORMANCE WHY AVIENT?

MEDICAL EQUIPMENT MANUFACTURER C L O S E D S Y S T E M D R U G T R A N S F E R D E V I C E • A new material for a seal inside the next generation of closed system drug transfer device • Compliance with stringent regulatory standards: • Biocompatibility to ISO10993 • USP VI compliance • Provided regulatory support services and expertise throughout extensive medical approval process • Provided a custom formulation compliant with the highest healthcare regulatory standards • Enabled material to be manufactured and shipped globally Custom Versalloy™ HC 9220-90 Formulation KEY REQUIREMENTS WHY AVIENT?

Industrial Valle del Cinca S/N Apartado E-22300 Barbastro Spain Avient Corporation - Berea, OH Liquid Colorants and Additives for Plastics , 680 N. Page 2 of 4 https://abs.ez2xs.com https://abs.ez2xs.com A B S Q u al ity E va lu at io n s C er tif ic at io n E Avient Corporation - Cergy, France Design and Manufacture of Color and Additive Concentrates and Specialty Compounds , 14 Avenue de l'Eguillette Saint Ouen l'Aumône - 95310 France Avient Corporation - Esenyurt, Turkey Design and Manufacture of Specialty Engineered Thermoplastics Orhangazi Mah. 1683 Sok. Page 3 of 4 https://abs.ez2xs.com https://abs.ez2xs.com A B S Q u al ity E va lu at io n s C er tif ic at io n E Avient Corporation - Mountain Top, PA Manufacturing, Shipping and Receiving , 855 Oak Hill Road Mountain Top - PA 18707 United States Avient Corporation - Oricain (Pamplona), Spain Design and Manufacture of Color and Additive Concentrates and Specialty Compounds Pol.

Microsoft PowerPoint - Avient March IR - Fermium AVIENT CORPORATION (NYSE: AVNT) M A R C H 1 8 , 2 0 2 1 I R M E E T I N G S H O S T E D B Y F E R M I U M R E S E A R C H DISCLAIMER 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 26 Avient reflects 2021 estimated EBITDA of $510M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 11.3 18.6 14.3 13.6 13.3 12.2 10.7 28.8 26.3 23.3 14.6 12.4 11.7 11.6 11.2 11.0 10.6 10.3 9.6 9.1 8.5 7.2 A vi en t K W R A V Y R P M P P G G C P F U L H X L A L B E C L IF F F M C A S H F O E B N R C E G R A E M N S C L U N V R K R A H U N Median: 11.2xMedian: 13.5x SUMMARY: WHY INVEST IN AVIENT? SEGMENT HIGHLIGHTS U.S. & Canada 50% EMEA 26% Asia 16% Latin America 8% 2020 SEGMENT, END MARKET AND GEOGRAPHY 29 GEOGRAPHY REVENUESEGMENT FINANCIALS Consumer 23% Packaging 21%Industrial 15% Wire & Cable 6% Building & Construction 6% Electrical & Electronics 4% END MARKET REVENUE Transportation 10% Healthcare 15% All data reflects 2020 Pro forma for acquisition of the Clariant Masterbatch business. (1) The total company sales and EBITDA of $3,783M and $457M, respectively, include intercompany sales eliminations and corporate costs $2,043M $331M $709M $124M $1,110M $70M Sales EBITDA Distribution Specialty Engineered Materials Color Additives and Inks $457M$3,783M (1) Packaging 35% Consumer 23% Healthcare 8% Industrial 14% Building & Construction 8% Transportation 7% Wire & Cable 3% Electrical & Electronics 2% C O L O R , A D D I T I V E S & I N K S 2020 PF REVENUE | $2 .0 BILLION US & Canada 31% EMEA 40% Asia 22% Latin America 7% END MARKET REGION 30 2020 figures Pro forma for acquisition of the Clariant Masterbatch business S P E C I A LT Y E N G I N E E R E D M AT E R I A L S Consumer 24% Healthcare 10% Packaging 6% Wire & Cable(1) 24% Electrical & Electronics 13% Transportation 11% Industrial 10% Building & Construction 2% 2020 REVENUE | $709 MILLION END MARKET US & Canada 58% EMEA 23% Asia 19% REGION 31 (1) Approximately 50% of Wire and Cable sales are associated with Fiber Optic Cabling DI S TR IBU T I ON 2020 REVENUE | $1 .1 B ILL ION Healthcare 29% Consumer 25% Packaging 2% Industrial 20% Transportation 14% Electrical & Electronics 5% Building & Construction 4% Wire & Cable 1% US & Canada 82% Asia 3% Latin America 15% END MARKET REGION K E Y S U P P L I ER S 32 AMERICAS EMEA ASIA Consumer 26% Healthcare 19% Packaging 13% Industrial 16% Wire & Cable 7% Building & Construction 5% Electrical & Electronics 4% Packaging 34% Consumer 16%Healthcare 5% Industrial 17% Wire & Cable 10% Building & Construction 8% Electrical & Electronics 3% Packaging 32% Consumer 27% Healthcare 12% Industrial 6% Wire & Cable 6% Building & Construction 4% Electrical & Electronics 9% Transportation 10% Transportation 7% Transportation 4% 2020 figures Pro forma for acquisition of the Clariant Masterbatch business TOTA L C O M PA N Y R E G I O N A L S A L E S BY END MARKET (58% of sales) (26% of sales) (16% of sales) 33

INVESTMENT IN COMMERCIAL RESOURCES D R I V E S I N N O VAT I V E P R O D U C T P O R T F O L I O AN D S AL E S G R O W T H 19 160 270 2011 2019 2020E 0.16 0.20 0.26 0.34 0.42 0.50 0.58 0.72 0.79 0.81 0.85 11 12 13 14 15 16 17 18 19 20 21E 2.5x TARGET NET LEVERAGE BY 2021 ~$1Bn REPURCHASED OVER LAST 10 YEARS ~$350MM PAID OVER LAST 10 YEARS RETURNING VALUE TO SHAREHOLDERS 12 Free Cash Flow Dividends Share Repurchases Deleveraging Strong track record of cash generation put to work in M&A and return to shareholders while modestly levered 0.1 0.1 0.2 0.5 0.6 0.7 0.8 0.9 0.9 1.0 11 12 13 14 15 16 17 18 19 20 2.9x 2.5x 2020PF* 2021E Growing Dividend Cumulative Buybacks Net Leverage $ B n $ p e r s h a re *2020 estimate and Pro forma for acquisition of the Clariant Masterbatch business Cash Generation ~$270MM Another unique value creation lever at Avient is synergy capture with our recent acquisition of Clariant Masterbatch. D is t. ) R P M K W R P P G F U L A V Y G C P F M C IF F H X L H U N F O E E M N E C L S C L K R A A S H C E G R A A L B Median: 5%Median: 3% Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Source: Bloomberg market data as of November 9, 2020 Median: 82% Median: 73% HIGH FREE CASH FLOW CONVERSION 83 86 85 85 80 78 58 88 83 81 79 77 76 73 73 72 72 67 64 63 60 6 A v ie n t K W R R P M P P G F U L A V Y G C P F M C IF F U N V R B N R E M N E C L C E H X L F O E A S H G R A H U N K R A S C L A L B Net Debt / 2021E EBITDA (1) We typically operate at 2.5–3.0x net debt to EBITDA.

Microsoft PowerPoint - AVNT Q4 2022 Earnings Presentation AVIENT CORPORATION F O U R T H Q U A R T E R 2 0 2 2 R E S U L T S A N D 2 0 2 3 F I N A N C I A L G U I D A N C E (NYSE: AVNT) F E B R U A RY 1 5 , 2 0 2 3 DISCLAIMER Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Avient Specialty Formulators Other Specialty / Chemical Companies 2023E(%) 28 79 87 81 79 76 73 90 77 76 75 73 64 59 33 A vi en t K W R P P G F U L A V Y R P M F M C C E A S H H X L E C L H U N E M N S C L MULTIPLE EXPANSION Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of February 13, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $38.89. Avient 2011 and 2018 valuations reflect trailing 12 months EBITDA at December 31 of the respective years. 29 EV / 2023E EBITDA Historic Multiple 6.5 8.3 10.0 15.6 13.9 13.7 12.8 9.5 18.0 17.5 12.3 10.2 9.7 8.8 8.4 5.9 A vi en t (2 01 1) A vi en t (2 01 8) A vi en t K W R P P G R P M A V Y F U L H X L E C L F M C A S H S C L H U N E M N C E SEGMENT DATA U.S. & Canada 40% EMEA 37% Asia 18% Latin America 5% 2022 PRO FORMA SEGMENT, END MARKET AND GEOGRAPHY GEOGRAPHY REVENUESEGMENT FINANCIALS Consumer 20% Packaging 24% Industrial 15% Building and Construction 10% Telecommunications 4% Energy 4% Defense 6% END MARKET REVENUE (1) Total company adjusted EBITDA of $592M includes corporate costs $2,355M $402M $1,300M $272M Sales EBITDA Specialty Engineered Materials Color Additives and Inks $592M$3,653M (1) Transportation 9% Healthcare 8% 31 C O L O R , A D D I T I V E S & I N K S 2022 REVENUE | $2 .4 B ILL ION US & Canada 34% EMEA 38% Asia 20% Latin America 8% END MARKET REGION 32 Packaging 34% Consumer 21% Healthcare 8% Industrial 15% Transportation 8% Building & Construction 11% Telecommunications 1% Energy 2% S P E C I A LT Y E N G I N E E R E D M AT E R I A L S 2022 PRO FORMA REVENUE | $1 .3 B ILL ION END MARKET US & Canada 52% EMEA 35% Asia 13% REGION 33 Packaging 5% Consumer 19% Healthcare 8%Industrial 16% Transportation 10% Telecommunications 10% Energy 9% Defense 15% Building & Construction 8% Packaging 32% Consumer 27% Healthcare 8% Industrial 14% Building & Construction 5% Telecommunications 3% Energy 1% Defense 1% Asia (18% of sales) Transportation 9% 2022 PROFORMA AVIENT REGIONAL SALES BY END MARKET Packaging 27% Consumer 14% Healthcare 5% Industrial 17% Building & Construction 10% Energy 5% Defense 8% EMEA (37% of sales)Transportation 11% Packaging 13% Consumer 24% Healthcare 12% Industrial 15% Building & Construction 13% Energy 5% Defense 5% US & Canada (40% of sales) Transportation 7% Packaging 56% Consumer 23% Healthcare 4% Industrial 7% Building & Construction 4% Telecommunications 1% LATAM (5% of sales) Transportation 5% Telecommunications 3% Telecommunications 6% 34 Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.